Immunotherapy advances最新文献_第7页

Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity? 血浆置换治疗检查点抑制剂引起的严重免疫相关不良事件:早期的机会窗口?

Immunotherapy advances Pub Date : 2022-01-01 DOI: 10.1093/immadv/ltac012

Tamiko R Katsumoto, Kalin L Wilson, Vinay K Giri, Han Zhu, Shuchi Anand, Kavitha J Ramchandran, Beth A Martin, Muharrem Yunce, Srikanth Muppidi

{"title":"Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?","authors":"Tamiko R Katsumoto, Kalin L Wilson, Vinay K Giri, Han Zhu, Shuchi Anand, Kavitha J Ramchandran, Beth A Martin, Muharrem Yunce, Srikanth Muppidi","doi":"10.1093/immadv/ltac012","DOIUrl":"https://doi.org/10.1093/immadv/ltac012","url":null,"abstract":"Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of several advanced malignancies leading to durable remission in a subset of patients. Their rapidly expanding use has led to an increased frequency of immune-related adverse events (irAEs). The pathogenesis of irAEs is poorly understood but may involve aberrant activation of T cells leading to inflammatory cytokine release or production of pathogenic antibodies leading to organ damage. Severe irAEs can be extremely debilitating and, in some cases, life threatening. IrAEs may not always be corticosteroid responsive or may require excessively high, often toxic, corticosteroid doses. Therapeutic plasma exchange (PLEX) is a treatment modality that has shown promising results for the management of certain severe irAEs, including irAEs that are not mentioned in current treatment guidelines. PLEX may attenuate ongoing irAEs and prevent delayed irAEs by accelerating clearance of the ICI, or by acutely removing pathogenic antibodies, cytokines, and chemokines. Here, we summarize examples from the literature in which PLEX was successfully used for the treatment of irAEs. We posit that timing may be a critical factor and that earlier utilization of PLEX for life-threatening irAEs may result in more favorable outcomes. In individuals at high risk for irAEs, the availability of PLEX as a potential therapeutic mitigation strategy may encourage life-saving ICI use or rechallenge. Future research will be critical to better define which indications are most amenable to PLEX, particularly to establish the optimal place in the sequence of irAE therapies and to assess the ramifications of ICI removal on cancer outcomes.","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e3/b8/ltac012.PMC9257781.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9780090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Human neutralizing antibodies for SARS-CoV-2 prevention and immunotherapy. 用于 SARS-CoV-2 预防和免疫疗法的人类中和抗体。

IF 4.1

Immunotherapy advances Pub Date : 2021-12-30 eCollection Date: 2022-01-01 DOI: 10.1093/immadv/ltab027

Dongyan Zhou, Runhong Zhou, Zhiwei Chen

{"title":"Human neutralizing antibodies for SARS-CoV-2 prevention and immunotherapy.","authors":"Dongyan Zhou, Runhong Zhou, Zhiwei Chen","doi":"10.1093/immadv/ltab027","DOIUrl":"10.1093/immadv/ltab027","url":null,"abstract":"Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19). SARS-CoV-2 has been spreading worldwide since December 2019, resulting in the ongoing COVID-19 pandemic with 237 million infections and 4.8 million deaths by 11 October 2021. While there are great efforts of global vaccination, ending this pandemic has been challenged by issues of exceptionally high viral transmissibility, re-infection, vaccine-breakthrough infection, and immune escape variants of concern. Besides the record-breaking speed of vaccine research and development, antiviral drugs including SARS-CoV-2-specific human neutralizing antibodies (HuNAbs) have been actively explored for passive immunization. In support of HuNAb-based immunotherapy, passive immunization using convalescent patients' plasma has generated promising evidence on clinical benefits for both mild and severe COVID-19 patients. Since the source of convalescent plasma is limited, the discovery of broadly reactive HuNAbs may have significant impacts on the fight against the COVID-19 pandemic. In this review, therefore, we discuss the current technologies of gene cloning, modes of action, in vitro and in vivo potency and breadth, and clinical development for potent SARS-CoV-2-specific HuNAbs.","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":null,"pages":null},"PeriodicalIF":4.1,"publicationDate":"2021-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6b/e8/ltab027.PMC8755319.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40577052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

HBV-HCC treatment with mRNA electroporated HBV-TCR T cells. mRNA电穿孔HBV-TCR T细胞治疗HBV-HCC。

Immunotherapy advances Pub Date : 2021-12-24 eCollection Date: 2022-01-01 DOI: 10.1093/immadv/ltab026

Anthony T Tan, Antonio Bertoletti

引用次数: 3

Seven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexity. LAG-3的七个谜团:一个越来越复杂的多面免疫受体

Immunotherapy advances Pub Date : 2021-12-20 eCollection Date: 2022-01-01 DOI: 10.1093/immadv/ltab025

Stephanie E A Burnell, Lorenzo Capitani, Bruce J MacLachlan, Georgina H Mason, Awen M Gallimore, Andrew Godkin

{"title":"Seven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexity.","authors":"Stephanie E A Burnell, Lorenzo Capitani, Bruce J MacLachlan, Georgina H Mason, Awen M Gallimore, Andrew Godkin","doi":"10.1093/immadv/ltab025","DOIUrl":"10.1093/immadv/ltab025","url":null,"abstract":"Despite three decades of research to its name and increasing interest in immunotherapies that target it, LAG-3 remains an elusive co-inhibitory receptor in comparison to the well-established PD-1 and CTLA-4. As such, LAG-3 targeting therapies have yet to achieve the clinical success of therapies targeting other checkpoints. This could, in part, be attributed to the many unanswered questions that remain regarding LAG-3 biology. Of these, we address: (i) the function of the many LAG-3-ligand interactions, (ii) the hurdles that remain to acquire a high-resolution structure of LAG-3, (iii) the under-studied LAG-3 signal transduction mechanism, (iv) the elusive soluble form of LAG-3, (v) the implications of the lack of (significant) phenotype of LAG-3 knockout mice, (vi) the reports of LAG-3 expression on the epithelium, and (vii) the conflicting reports of LAG-3 expression (and potential contributions to pathology) in the brain. These mysteries which surround LAG-3 highlight how the ever-evolving study of its biology continues to reveal ever-increasing complexity in its role as an immune receptor. Importantly, answering the questions which shroud LAG-3 in mystery will allow the maximum therapeutic benefit of LAG-3 targeting immunotherapies in cancer, autoimmunity and beyond.","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895726/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48745506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

100 years post-insulin: immunotherapy as the next frontier in type 1 diabetes. 胰岛素之后的 100 年：免疫疗法是 1 型糖尿病的下一个前沿领域。

Immunotherapy advances Pub Date : 2021-11-24 eCollection Date: 2021-01-01 DOI: 10.1093/immadv/ltab024

James A Pearson, Eoin F McKinney, Lucy S K Walker

引用次数: 0

Editor's Note: Relates to: 'Immuno-antibiotics: targeting microbial metabolic pathways sensed by unconventional T cells'. 编者注:涉及:“免疫抗生素:靶向由非常规T细胞感知的微生物代谢途径”。

Immunotherapy advances Pub Date : 2021-11-19 eCollection Date: 2021-01-01 DOI: 10.1093/immadv/ltab023

Matthias Eberl, Eric Oldfield, Thomas Herrmann

引用次数: 0

Harnessing immunometabolism for cardiovascular health and cancer therapy. 利用免疫代谢促进心血管健康和癌症治疗。

IF 4.1

Immunotherapy advances Pub Date : 2021-11-09 eCollection Date: 2021-01-01 DOI: 10.1093/immadv/ltab021

Angela Markovska, Henk S Schipper, Marianne Boes

引用次数: 0

Potential human immunotherapeutics for plague. 鼠疫的潜在人类免疫疗法。

IF 4.1

Immunotherapy advances Pub Date : 2021-10-05 eCollection Date: 2021-01-01 DOI: 10.1093/immadv/ltab020

Voahangy Andrianaivoarimanana, Lovasoa Nomena Randriantseheno, Kristoffer M Moore, Nicola J Walker, Steven G Lonsdale, Sarah Kempster, Neil A Almond, Minoarisoa Rajerison, E Diane Williamson

{"title":"Potential human immunotherapeutics for plague.","authors":"Voahangy Andrianaivoarimanana, Lovasoa Nomena Randriantseheno, Kristoffer M Moore, Nicola J Walker, Steven G Lonsdale, Sarah Kempster, Neil A Almond, Minoarisoa Rajerison, E Diane Williamson","doi":"10.1093/immadv/ltab020","DOIUrl":"10.1093/immadv/ltab020","url":null,"abstract":"Two monoclonal antibodies directed to the V antigen of Yersinia pestis have been tested for protective efficacy in a murine model of bubonic plague. Mice were infected with a current clinical isolate from Madagascar, designated Y. pestis 10-21/S. Mab7.3, delivered to mice intra-periteoneally at either 24 h prior to, or 24 h post-infection, was fully protective, building on many studies which have demonstrated the protective efficacy of this Mab against a number of different clinical isolates of Y. pestis. Mab 29.3, delivered intra-peritoneally at either -24 h or +24 h, protected 4/5 mice in either condition; this has demonstrated the protective efficacy of this Mab in vivo for the first time. These results add to the cumulative data about Mab7.3, which is currently being humanized and highlight its potential as a human immunotherapeutic for plague, which is an enduring endemic disease in Madagascar and other regions of Africa, Asia, and South America.","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":null,"pages":null},"PeriodicalIF":4.1,"publicationDate":"2021-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327098/pdf/ltab020.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40578949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oral tolerance as antigen-specific immunotherapy. 口服耐受作为抗原特异性免疫疗法。

Immunotherapy advances Pub Date : 2021-08-25 eCollection Date: 2021-01-01 DOI: 10.1093/immadv/ltab017

Natália Pinheiro-Rosa, Lícia Torres, Mariana de Almeida Oliveira, Marcos Felipe Andrade-Oliveira, Mauro Andrade de Freitas Guimarães, Monique Macedo Coelho, Juliana de Lima Alves, Tatiani Uceli Maioli, Ana M Caetano Faria

{"title":"Oral tolerance as antigen-specific immunotherapy.","authors":"Natália Pinheiro-Rosa, Lícia Torres, Mariana de Almeida Oliveira, Marcos Felipe Andrade-Oliveira, Mauro Andrade de Freitas Guimarães, Monique Macedo Coelho, Juliana de Lima Alves, Tatiani Uceli Maioli, Ana M Caetano Faria","doi":"10.1093/immadv/ltab017","DOIUrl":"https://doi.org/10.1093/immadv/ltab017","url":null,"abstract":"Oral tolerance is a physiological phenomenon described more than a century ago as a suppressive immune response to antigens that gain access to the body by the oral route. It is a robust and long-lasting event with local and systemic effects in which the generation of mucosally induced regulatory T cells (iTreg) plays an essential role. The idea of using oral tolerance to inhibit autoimmune and allergic diseases by oral administration of target antigens was an important development that was successfully tested in 1980s. Since then, several studies have shown that feeding specific antigens can be used to prevent and control chronic inflammatory diseases in both animal models and clinically. Therefore, oral tolerance can be classified as an antigen-specific form of oral immunotherapy (OIT). In the light of novel findings on mechanisms, sites of induction and factors affecting oral tolerance, this review will focus on specific characteristics of oral tolerance induction and how they impact in its therapeutic application.","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40578945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

The clinical correlates of vaccine-induced immune thrombotic thrombocytopenia after immunisation with adenovirus vector-based SARS-CoV-2 vaccines. 使用基于腺病毒载体的 SARS-CoV-2 疫苗免疫后，疫苗诱发免疫性血栓性血小板减少症的临床相关性。

Immunotherapy advances Pub Date : 2021-08-17 eCollection Date: 2021-01-01 DOI: 10.1093/immadv/ltab019

Eleanor R Gaunt, Neil A Mabbott

{"title":"The clinical correlates of vaccine-induced immune thrombotic thrombocytopenia after immunisation with adenovirus vector-based SARS-CoV-2 vaccines.","authors":"Eleanor R Gaunt, Neil A Mabbott","doi":"10.1093/immadv/ltab019","DOIUrl":"10.1093/immadv/ltab019","url":null,"abstract":"We are at a critical stage in the COVID-19 pandemic where vaccinations are being rolled out globally, in a race against time to get ahead of the SARS-CoV-2 coronavirus and the emergence of more highly transmissible variants. A range of vaccines have been created and received either emergency approval or full licensure. To attain the upper hand, maximum vaccine synthesis, deployment, and uptake as rapidly as possible is essential. However, vaccine uptake, particularly in younger adults is dropping, at least in part fuelled by reports of rare complications associated with specific vaccines. This review considers how vaccination with adenovirus vector-based vaccines against the SARS-CoV-2 coronavirus might cause rare cases of thrombosis and thrombocytopenia in some recipients. A thorough understanding of the underlying cellular and molecular mechanisms that mediate this syndrome may help to identify methods to prevent these very rare, but serious side effects. This will also help facilitate the identification of those at highest risk from these outcomes, so that we can work towards a stratified approach to vaccine deployment to mitigate these risks.","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385946/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10732190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0